JP2020533955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533955A5 JP2020533955A5 JP2020502655A JP2020502655A JP2020533955A5 JP 2020533955 A5 JP2020533955 A5 JP 2020533955A5 JP 2020502655 A JP2020502655 A JP 2020502655A JP 2020502655 A JP2020502655 A JP 2020502655A JP 2020533955 A5 JP2020533955 A5 JP 2020533955A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- binding fragment
- nos
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 30
- 238000000034 method Methods 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 229940127121 immunoconjugate Drugs 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 102000001189 Cyclic Peptides Human genes 0.000 claims 2
- 108010069514 Cyclic Peptides Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 238000012879 PET imaging Methods 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023039300A JP2023086132A (ja) | 2017-07-18 | 2023-03-14 | アミロイドベータに対する抗体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CAPCT/CA2017/050866 | 2017-07-18 | ||
| PCT/CA2017/050866 WO2018014126A1 (en) | 2016-07-18 | 2017-07-18 | Antibodies to amyloid beta |
| US15/808,842 US20180125920A1 (en) | 2016-11-09 | 2017-11-09 | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| US15/808,842 | 2017-11-09 | ||
| US201862622126P | 2018-01-25 | 2018-01-25 | |
| US62/622,126 | 2018-01-25 | ||
| PCT/CA2018/050875 WO2019014768A1 (en) | 2017-07-18 | 2018-07-18 | ANTI-BETA-AMYLOID ANTIBODY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039300A Division JP2023086132A (ja) | 2017-07-18 | 2023-03-14 | アミロイドベータに対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533955A JP2020533955A (ja) | 2020-11-26 |
| JP2020533955A5 true JP2020533955A5 (enExample) | 2021-08-26 |
| JP7330164B2 JP7330164B2 (ja) | 2023-08-21 |
Family
ID=65014947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502655A Active JP7330164B2 (ja) | 2017-07-18 | 2018-07-18 | アミロイドベータに対する抗体 |
| JP2023039300A Pending JP2023086132A (ja) | 2017-07-18 | 2023-03-14 | アミロイドベータに対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039300A Pending JP2023086132A (ja) | 2017-07-18 | 2023-03-14 | アミロイドベータに対する抗体 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3574020B1 (enExample) |
| JP (2) | JP7330164B2 (enExample) |
| CA (1) | CA3070085A1 (enExample) |
| ES (1) | ES2984844T3 (enExample) |
| WO (1) | WO2019014768A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3004482A1 (en) | 2015-11-09 | 2017-05-18 | Neil R. Cashman | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5735814A (en) | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
| JP2000514094A (ja) | 1997-04-17 | 2000-10-24 | レオネ，パオラ | 脳への遺伝子治療のための送達システム |
| US7012061B1 (en) | 1998-10-19 | 2006-03-14 | New York University | Method for increasing the permeability of the blood brain barrier |
| EA006606B1 (ru) | 2000-02-24 | 2006-02-24 | Вашингтон Юниверсити | Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения |
| WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| ES2344645T3 (es) | 2003-02-10 | 2010-09-02 | Applied Molecular Evolution, Inc. | Moleculas de union al abeta. |
| CN1562050A (zh) | 2004-03-24 | 2005-01-12 | 中国海洋大学 | 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用 |
| KR20070094890A (ko) * | 2004-10-25 | 2007-09-27 | 머크 앤드 캄파니 인코포레이티드 | 안티 ａｄｄｌ 항체 및 그 용도 |
| US20060129126A1 (en) | 2004-11-19 | 2006-06-15 | Kaplitt Michael G | Infusion device and method for infusing material into the brain of a patient |
| US20060257396A1 (en) * | 2004-12-15 | 2006-11-16 | Jacobsen Jack S | Abeta antibodies for use in improving cognition |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| JP2008545663A (ja) | 2005-05-27 | 2008-12-18 | クイーンズ ユニバーシティ アット キングストン | タンパク質フォールディング障害の治療 |
| CA2632828C (en) | 2005-12-12 | 2012-07-10 | F. Hoffmann-La Roche Ag | Antibodies against amyloid beta with glycosylation in the variable region |
| WO2008088983A1 (en) | 2007-01-18 | 2008-07-24 | Eli Lilly And Company | PEGYLATED Aβ FAB |
| AU2008311366B2 (en) | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| WO2009086539A2 (en) | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| AT506820B1 (de) | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| CA2723995A1 (en) | 2008-06-12 | 2009-12-17 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| ES2734552T3 (es) | 2010-04-16 | 2019-12-10 | Ac Immune Sa | Compuestos novedosos para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide |
| WO2017025918A1 (en) * | 2015-08-11 | 2017-02-16 | Novartis Ag | 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer |
| US10774120B2 (en) * | 2015-11-09 | 2020-09-15 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
| KR102550991B1 (ko) * | 2016-07-18 | 2023-07-04 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에 대한 항체 |
| US20180125920A1 (en) * | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
-
2018
- 2018-07-18 ES ES18835520T patent/ES2984844T3/es active Active
- 2018-07-18 CA CA3070085A patent/CA3070085A1/en active Pending
- 2018-07-18 EP EP18835520.0A patent/EP3574020B1/en active Active
- 2018-07-18 JP JP2020502655A patent/JP7330164B2/ja active Active
- 2018-07-18 WO PCT/CA2018/050875 patent/WO2019014768A1/en not_active Ceased
-
2023
- 2023-03-14 JP JP2023039300A patent/JP2023086132A/ja active Pending